<DOC>
	<DOCNO>NCT00006135</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine efficacy long term suppressive therapy oral acyclovir infant herpes simplex virus infection limit skin , eye , mouth . II . Determine neurologic outcome patient treat regimen . III . Evaluate significance positive cerebrospinal fluid ( CSF ) polymerase chain reaction ( PCR ) result CSF parameter remain normal patient . IV . Correlate time first positive CSF PCR result first 12 month life clinical neurological assessment patient treat regimen . V. Determine whether continuous administration drug suppress recurrent skin lesion patient . VI . Determine safety regimen patient .</brief_summary>
	<brief_title>Phase III Randomized Study Oral Acyclovir Infants With Herpes Simplex Virus Infection Limited Skin , Eyes , Mouth</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , multicenter study . All patient undergo lumbar puncture receive acyclovir IV every 8 hour Days 1-14 . On Day 12 , patient may undergo lumbar puncture ( discretion investigator ) . Whole blood obtain herpes simplex virus PCR analysis . Upon completion intravenous therapy , patient negative CSF PCR randomize one two treatment arm . Arm I : Patients receive oral acyclovir three time daily 6 month . Arm II : Patients receive placebo three time daily 6 month . In case cutaneous recurrence first 12 month study , patient receive open label oral acyclovir ( CSF PCR negative ) acyclovir IV ( CSF PCR positive ) 5 day . Patients may may continue study drug follow treatment . Patients follow 6 , 12 , 24 , 36 , 48 , 60 month age .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Infants diagnose herpes simplex virus infection limit skin , eye , mouth ; HSV1 HSV2 isolate cutaneous lesion , conjunctiva , oropharynx ( presence skin lesion require ) ; normal CSF index : WBC le 22/mm3 protein less 115 mg/dL term infant OR WBC le 25/mm3 protein less 220 mg/dL preterm infant ; evidence CNS involvement CT contrast , MRI gadolinium , head ultrasound ; visceral dissemination ( normal liver function test , normal chest xray , etc . ) ; negative CSF PCR result Birth weight least 800 grams Prior/Concurrent Therapy No concurrent nurse mother receive acyclovir , valacyclovir , famciclovir longer 120 hour 5 day ; prior prophylactic acyclovir risk herpes simplex virus infection Patient Characteristics Renal : Creatinine great 1.5 mg/dL Cardiovascular : No prior grade 3 4 intraventricular hemorrhage Other : No infant know born HIVpositive woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>herpes simplex virus infection</keyword>
	<keyword>herpesvirus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>